Since Sildenafil improves exercise capacity and quality of life in PAH patients [58] and pulmonary hemodynamics at rest and during exercise in patients with COPD-associated PH, it seems that inhibition of PDE5 could be a reliable target for patients suffering from vascular alterations. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.